Mizuho initiated coverage of Celldex (CLDX) with an Outperform rating and $48 price target The firm sees barzolvolimab as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. Mizuho added that it believes barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex initiated with an Underweight at Barclays
- Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
- Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
- Celldex announces new barzolvolimab data at EADV congress
- Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study